[go: up one dir, main page]

WO2008145013A8 - Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine - Google Patents

Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine Download PDF

Info

Publication number
WO2008145013A8
WO2008145013A8 PCT/CN2008/001014 CN2008001014W WO2008145013A8 WO 2008145013 A8 WO2008145013 A8 WO 2008145013A8 CN 2008001014 W CN2008001014 W CN 2008001014W WO 2008145013 A8 WO2008145013 A8 WO 2008145013A8
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
lidamycin
targeting peptide
ldp
apoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2008/001014
Other languages
English (en)
Chinese (zh)
Other versions
WO2008145013A1 (fr
Inventor
Yanbo Zheng
Yongsu Zhen
Boyang Shang
Xiujun Liu
Shuying Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Biotechnology of CAMS and PUMC
Original Assignee
Institute of Medicinal Biotechnology of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Biotechnology of CAMS and PUMC filed Critical Institute of Medicinal Biotechnology of CAMS and PUMC
Publication of WO2008145013A1 publication Critical patent/WO2008145013A1/fr
Publication of WO2008145013A8 publication Critical patent/WO2008145013A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une protéine hybride NGR-LDP-AE qui comprend un peptide de ciblage du CD13, une apoprotéine lidamycine (LDP) et un chromophore énédiyne (AE) sous forme active associé au LDP. Cette protéine hybride peut servir pour certains traitements de cancer précis.
PCT/CN2008/001014 2007-05-25 2008-05-26 Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine Ceased WO2008145013A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2007101072702A CN101070350B (zh) 2007-05-25 2007-05-25 针对cd13的靶向肽与力达霉素构成的强化融合蛋白ngr-ldp-ae
CN200710107270.2 2007-05-25

Publications (2)

Publication Number Publication Date
WO2008145013A1 WO2008145013A1 (fr) 2008-12-04
WO2008145013A8 true WO2008145013A8 (fr) 2009-07-30

Family

ID=38897778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/001014 Ceased WO2008145013A1 (fr) 2007-05-25 2008-05-26 Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine

Country Status (2)

Country Link
CN (1) CN101070350B (fr)
WO (1) WO2008145013A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070350B (zh) * 2007-05-25 2011-03-23 中国医学科学院医药生物技术研究所 针对cd13的靶向肽与力达霉素构成的强化融合蛋白ngr-ldp-ae
CN102286074B (zh) * 2011-07-06 2013-09-11 苏州工业园区晨健抗体组药物开发有限公司 一种cd13靶向肽ngr及其应用
CN108721641B (zh) * 2017-04-14 2021-05-11 中国医学科学院医药生物技术研究所 抗cd30抗体与力达霉素的抗体药物偶联物、制备方法及其用途
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
CN110616254A (zh) * 2019-08-29 2019-12-27 武汉金开瑞生物工程有限公司 一种pet系列载体正向测序引物及测序方法
EP3882257A1 (fr) * 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Conjugués ngr et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125183C (zh) * 2000-08-10 2003-10-22 深圳市盛康达生物技术有限公司 抗肿瘤抗生素力达霉素的制备新方法
EP1651766A2 (fr) * 2003-08-05 2006-05-03 Wisconsin Alumni Research Foundation Fusions de vecteurs cibles pour administrer des agents chimiotherapeutiques
CN100352838C (zh) * 2005-03-24 2007-12-05 中国医学科学院医药生物技术研究所 表皮生长因子受体靶向短肽与力达霉素构成的抗肿瘤基因工程融合蛋白
CN101070350B (zh) * 2007-05-25 2011-03-23 中国医学科学院医药生物技术研究所 针对cd13的靶向肽与力达霉素构成的强化融合蛋白ngr-ldp-ae

Also Published As

Publication number Publication date
CN101070350A (zh) 2007-11-14
CN101070350B (zh) 2011-03-23
WO2008145013A1 (fr) 2008-12-04

Similar Documents

Publication Publication Date Title
EP3272773B8 (fr) Peptides de ciblage lysosomal et leurs utilisations
PH12016500081B1 (en) Immunoglobulin variants and uses thereof
WO2008052187A3 (fr) Anticorps et immunoconjugués, et leurs utilisations
WO2010065954A3 (fr) Peptides de liaison à sparc et leurs utilisations
WO2009067636A3 (fr) Polypeptides d'insuline modifiés et leurs utilisations
WO2009155556A3 (fr) Peptides de ciblage de crkl
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EP2214700A4 (fr) Produits d'assemblage semi-synthétiques obtenus par fusion de peptide glp-1/fc, procédés et utilisations
WO2010096603A3 (fr) Peptides ciblant le cancer et leur utilisation en cancérothérapie
IL205681A0 (en) Anti-mesothelin antibodies and uses therefor
WO2008145013A8 (fr) Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
ZA201002848B (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AU2010226726A8 (en) Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
WO2007121269A3 (fr) N-aryl-n'alkyle sulfamides utilisés comme inhibiteurs de mek
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
PL2140269T3 (pl) Podpis białkowy/znaczniki do wykrywania gruczolakoraka
WO2007118660A3 (fr) Vaccin multipeptidique au her-2/neu
WO2008143668A3 (fr) Indoléamine-2, 3-dioxygénase-2
WO2008044076A3 (fr) Anticorps et leurs utilisations
WO2010014922A3 (fr) Marqueurs de purification de protéine et leurs utilisations
EP2010570B8 (fr) Therapie vers cathepsin s
WO2008121963A3 (fr) Compositions et procédés de silençage de gènes
EP2091971A4 (fr) Vectorisation therapeutique de proteines d'escorte
WO2007102946A3 (fr) Polypeptides cristallins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08748532

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08748532

Country of ref document: EP

Kind code of ref document: A1